中国新药杂志

新型冠状病毒肺炎临床治疗药物最新研究进展

PDF下载

顾觉奋

中国新药杂志 | 抗新型冠状病毒药物研究专栏 2021,30(2): 154-161

收起

中国新药杂志 |抗新型冠状病毒药物研究专栏 2021 , 30 (2) : 154 -161

新型冠状病毒肺炎临床治疗药物最新研究进展

全屏

[Author(id=1322627318124762082, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322627317369787354, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=juefengu@126.com, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1322627318208648164, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322627317369787354, authorId=1322627318124762082, language=EN, stringName=Jue-fen GU, firstName=Jue-fen, middleName=null, lastName=GU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Institute of Life Science and Technology, China Pharmaceutical University, Nanjing 210009, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322627318279951333, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322627317369787354, authorId=1322627318124762082, language=CN, stringName=顾觉奋, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=中国药科大学生命与科学学院，南京　210009, bio={"content":"

顾觉奋，女，教授，主要从事微生物制药教学与研究。E-mail：juefengu@126.com。

"}, bioImg=null, bioContent=

顾觉奋，女，教授，主要从事微生物制药教学与研究。E-mail：juefengu@126.com。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322627318028293086, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322627317369787354, xref=null, ext=[AuthorCompanyExt(id=1322627318036681695, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322627317369787354, companyId=1322627318028293086, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Institute of Life Science and Technology, China Pharmaceutical University, Nanjing 210009, China), AuthorCompanyExt(id=1322627318049264608, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322627317369787354, companyId=1322627318028293086, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国药科大学生命与科学学院，南京　210009)])])]

顾觉奋

作者信息

中国药科大学生命与科学学院，南京　210009

作者简介:

顾觉奋，女，教授，主要从事微生物制药教学与研究。E-mail：juefengu@126.com。

The latest progress in research on clinical therapeutic agents of COVID-19

Jue-fen GU

Affiliations

Institute of Life Science and Technology, China Pharmaceutical University, Nanjing 210009, China

出版时间: 2021-01-30

文章导航

摘要

收起

新型冠状病毒肺炎（coronavirus disease 2019，COVID-19）正在世界范围内流行。作为冠状病毒，新型冠状病毒（SARS-CoV-2）和严重急性呼吸综合征冠状病毒（SARS-CoV）都通过人血管紧张素转化酶2（ACE2）受体侵入宿主细胞。面对疫情异常严峻的现状，目前尚缺乏疫苗和尚无特异性针对该病毒的抗病毒药物，临床上仍以支持治疗和对症治疗为主。本文简单介绍了新型冠状病毒和ACE2的关系及作用机制，总结了潜在抗新型冠状病毒治疗药物的最新临床疗效，及其相关药物可能的作用机制，以便充分了解COVID-19的发展过程和药物研究方向，为后续探讨COVID-19药物治疗和疫苗研发提供思路。

关键词

新型冠状病毒肺炎 / 新型冠状病毒 / 最新临床研究进展 / 治疗药物 / 作用机制

Abstract

收起

COVID-19 has been becoming popular all over the worldwide. As a coronavirus, both SARS-CoV-2 and SARS-CoV invade host cells through ACE2 receptor. Facing the extremely severe epidemic situation of COVID-19, there is a lack of vaccine and specific antiviral drug for this virus at present. Clinically, supportive treatment and symptomatic treatment are still the main measures. The roles of COVID-19 and ACE2 in SARS-CoV-2 were briefly introduced in this article. The results of the latest clinical trials of potential anti-COVID-19 drugs and the possible mechanisms of action of related drugs were summarized, in order to fully understand the development process of COVID-19 and direction of drug research thus to provide ideas for further study of COVID-19 drug therapy and vaccine development.

Key words

COVID-19 / SARS-CoV-2 / latest clinical research progress / therapeutic drug / mechanism of action

引用本文

顾觉奋. 新型冠状病毒肺炎临床治疗药物最新研究进展. 中国新药杂志, 2021 , 30 (2) : 154 -161 .

Jue-fen GU. The latest progress in research on clinical therapeutic agents of COVID-19[J]. Chinese Journal of New Drugs, 2021 , 30 (2) : 154 -161 .

参考文献

收起

文献

收起

参考文献引证文献

排序方式：

[1]

World Health Organization: Clinical management of severe acute respiratory infection when Novel coronavirus (nCoV) infection is suspected: Interim Guidance[EB/OL]. [2020-01-12]. https://www.mokadou.com/p/609.

[2]

HOFFMANN M, KLEINE-WEBER H, KRUEGER N, et al. The novel coronavirus 2019 (2019-NcOv) uses the SARS coronavirus receptor ACE2 and the cellular for entry into protease TMPRSS2 target cells[EB/OL]. BioRxiv, 2020, doi.org/10.1101/2020.01.31.929042.

[3]

CROXTALL JD, PERRY CM. Lopinavir/ritonavir: a review of its use in the management of HIV-1 infection[J]. Drugs, 2010, 70(14): 1885-1915.

[4]

腾讯网. 冠状病毒治疗药物研究进展[EB/OL]. [2020-05-28]. https://xw.qq.com/cmsid/20200217A00C7V00.

[5]

中国政府网. 关于印发新型冠状病毒感染的肺炎诊疗方案(试行第三版)的通知[EB/OL]. [2020-02-22]. http://www.gov.cn/zhengce/zhengceku/2020-01/23/content_5471832.htm.

[6]

HUNG IFN, LUNG KC, EUGENE YK, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial[J]. Lancet, 2020, DOI: 10.1016/S0140-6736(20)31042-4.

[7]

TCHESNOKOV EP, FENG JY, PORTER DP, et al. Mechanism of inhibition of Ebola virus RNA-dependent RNA polymerase by remdesivir[J]. Viruses, 2019, 11(4): 326.

[8]

凤凰网. 瑞德西韦治疗新冠综述: 埃博拉试验中死亡率高, 但仍值得期待[EB/OL]. [2020-03-09]. http://www.finance.ifeng.com/c/7uhnleF7Xu8.

[9]

MCMULLAN LK, FLINT M, CHAKRABARTI A, et al. Characterisation of infectious Ebola virus from the ongoing outbreak to guide response activities in the Democratic Republic of the Congo: a phylogenetic and in vitro analysis[J]. Lancet Infect Dis, 2019, 19(9): 1023-1032.

[10]

YIN WC, MAO CY, LUAN XD, et al. Structural base for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir[J]. Science, 2020, DOI: 10.1126/science.abc1560.

[11]

BEIGEL JH, TOMASHEK KM, DODD LE, et al. Remdesivir for the treatment of Covid-19——preliminary report[J]. N Engl J Med, 2020, doi: 10.1056/NEJMoa2007764.

[12]

SHEAHAN TP, SIMS AC, LEIST SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV[J]. Nat Commun, 2020, 11(1): 1-14.

[13]

GREIN J, OHMAGARI N, SHIN D, et al. Compassionate use of remdesivir for patients with severe covid-19[J]. N Engl J Med, 2020, 382(24): 2327-2336.

[14]

搜狐网. 为什么说阿比多尔是抗新冠病毒的潜在有效药?[EB/OL]. [2020-02-07]. https://www.sohu.com/a/371293161_100191057.

[15]

腾讯网. 李兰娟院士团队最新成果, 阿比朵尔、达芦那韦能有效抑制冠状病毒[EB/OL]. [2020-02-04]. https://www.xw.qq.com/cmsid/20200204A0P8QH00.

[16]

新华网. 新型冠状病毒肺炎诊疗方案(试行第六版)及解读[EB/OL]. [2020-02-19]. http://www.xinhuanet.com/health/2020-02/19/c_1125596339.htm.

[17]

搜狐网. 抗流感新药可能成为新冠肺炎的克星, 刚刚获批上市[EB/OL]. [2020-02-17]. https://www.sohu.com/a/373792757_114930.

[18]

BIOFOUNT网. 法匹拉韦三磷酸(T-705)核糖基三磷酸对流感病毒RNA聚合酶的作用机理[EB/OL]. [2020-06-01]. https://www.bio-fount.com/cn/content/275.html.

[19]

财经网. 国务院联防联控机制3月17日举行发布会[EB/OL]. [2020-03-17]. https://baijiahao.baidu.com/s?id=1661600941217584267&wfr=spider&for=pc.

[20]

Al-BARI MAA. Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases[J]. Pharmacol Res Perspect, 2017, 5(1): e00293.

[21]

MEHRA MR, DESAI SS, RUSCHITZKA F, et al. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis[J]. Lancet, 2020, doi: 10.1016/S0140-6736(20)31180-6.

[22]

WANG M, CAO R, ZHANG L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro[J]. Cell Res, 2020, 30(3): 269-271.

[23]

腾讯网. 科技部青睐的新冠候选药磷酸氯喹有没有致命性风险?[EB/OL]. [2020-02-28]. https://xw.qq.com/cmsid/20200228A0OHV200?ivk.

[24]

吴昊, 王佳琪, 杨雨薇, 等. 基于网络药理学和分子对接技术初步探索“清肺排毒汤”抗新型冠状病毒肺炎作用机制[J]. 药学学报, 2020, 55(3): 374-383.

[25]

HU K, GUAN WJ, ZHONG NS, et al. Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: a multicenter, prospective, randomized controlled trial[J]. Phytomedicine, 2020, DOI: 10.1016/j.phymed.2020.153242.

[26]

ZHU FC, LI YH, WEI C, et al. Safety, tolerabitily, and immunogenicity of a recombinunt adenovirus type-5 Vectored COVID-19Vaccine[EB/OL]. [2020-05-22]. https://doi.org/10.1016/S0140-6736.

[27]

ZHU FC, GUAN XH, LI TH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial[J]. Lancet, 2020, DOI: 10.1016/S0140-6736(20)31605-6.

[28]

SHI R, SHAN C, DUAN X. et al. A human neutralizing antibody targets the receptor binding site of SARS-CoV-2[J]. Nature, 2020, DOI: 10.1038/s41586-020-2381-y.

[29]

BIOTECH网. 共抗疫情《自然》杂志刊登君实生物新冠中和抗体阶段性研究成果[EB/OL]. [2020-05-27]. http://www.acnnewswire.com/press-release/simplifiedchinese/59239.

[30]

CAO YL, SU B, XIE SN, et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patient's B cells[J]. Cell, 2020, 182(1): 73-84.

[31]

WU YL, LI C, YING TL, et al. Identification of human single-domain antibodies against SARS-CoV-2[J]. Cell Host Microbe, 2020, 27(6): 891-893.e5.

[32]

TIAN XL, LI C, HUANG A, et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody[J]. Emerg Microbes Infect, 2020, 9(1): 382-385.

[33]

新浪网. 美疾控中心预计: 8月15日前美国新冠死亡病例将超16.4万[EB/OL]. [2020-07-24]. https://k.sina.com.cn/article_1686546714_6486a91a0200155kj.html?from=health.

[34]

搜孤网. 13000名志愿者接种! 中国研发的新冠疫苗在土耳其启动第三期临床试验[EB/OL]. [2020-09-16]. https://m.sohu.com/a/419224384_162758.

[35]

腾讯网. 科技部部长: 中国已有11款新冠疫苗进入临床试验, 其中4款进入三期[EB/OL]. [2020-09-18]. https://new.qq.com/rain/a/20200918A04H5U.

[36]

白佳坤, 马晓阳, 李霄鹤, 等. 新型冠状病毒治疗靶点及药物研究进展[J]. 今日药学, 2020, publish ahead of print.

[37]

金翔, 俞庆龄, 张璐楠, 等. 针对新型冠状病毒的DNA疫苗研究进展[J]. 中国新药杂志, 2020, 29(21): 2425-2433.

2021年第30卷第2期

PDF下载

引用本文

BibTeX

文章信息

首发时间：2026-10-29
出版时间：2021-01-30

补充材料

相关文章

文章信息

作者

出版历史

录用日期：2020-08-25

基金

作者信息

中国药科大学生命与科学学院，南京　210009

参考文献

分享链接

https://castjournals.cast.org.cn/joweb/zgxyzz/CN/1322627317369787354

分享至

全文二维码

扫描看全文

引用本文

BibTeX

本文的引用情况

2种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT